Warning Letter Watch

On April 4, 2017 the FDA issued a letter to a major pharmaceutical company that had responded to Warning Letter on cGMP violations. The letter contains information regarding data integrity issues stating: “Your quality system does not adequately ensure the accuracy and integrity of data... Read More...